Drug Discovery and Development

Big Pharma clicks soared, but new cell therapies made you buzz: What drove biopharma interest in 2023?

The big Big Pharma stats you couldn't ignore

By |

biotech

[Adobe Stock]

Despite biopharma’s 2023 layoffs and challenges, innovation won your clicks last year with over 130,000 of them on our Pharma 50 report alone. But while giants dominated, your clicks showed disruptive tech wasn’t far behind. The next-most popular article was a roundup of 100 trailblazing cell and gene therapy companies with more than 80,000 views. Other hits included companies putting AI in drug discovery and development, and the ever-popular biotech startup watch – proof that solutions, not just statistics, attract attention. Rounding out the top five was a roundup of biotech job cuts and openings.

2023 biopharma innovation in the spotlight on Linkedin

But over on LinkedIn, innovation was also a driver of interest. Topics on women’s health, such as Organon doubling down on women’s health, novel approaches to mental illness at Gate Neuro, and head-to-head comparisons of blockbuster weight loss drugs sparked the most reactions.

Other stories that fared best on the social media platform included CinCor’s stock surge after the AstraZeneca buyout announcement, the first episode of “AI Meets Life Sci,” and Gate Neurosciences’ novel approaches in depression treatment dominating engagements.

In 2023, LinkedIn engagement with Drug Discovery & Development content surged, with a 41.6% increase in impressions. Overall engagement was up 39.8%.

AI and techbio on display

My own LinkedIn profile witnessed a jump in engagement overall. Some of the best-performing articles there include an exploration of Recursion’s Phenom-Beta partnership with NVIDIA (11,475 impressions). The partnership centers around democratizing access to phenomics (the large-scale study of phenotypes) by converting images of human cells into mathematical biology models, which has the potential to accelerate drug discovery and personalized medicine.

An article on the techbio landscape was next-most popular with 9,987 impressions followed by an examination of Virginia’s life sciences boom with 8,803 impressions.

The data and engagement metrics across LinkedIn and Google Analytics tell one clear story: you aren’t just looking for trends in biopharma, you want to create them. My own experience with LinkedIn shows that giving industry leaders a platform to share their ideas can resonate widely. Expect 2024’s DD&D coverage to amplify these voices more than ever. But we want to know: Do you see an unheard story the industry needs to consider? Share, so we can ensure we aren’t missing a story that deserves the spotlight. If something comes to mind, hit me up on LinkedIn.

Filed Under: Biotech, Cell & gene therapy, Data science, machine learning and AI
Tagged With: , , , , ,
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Search Drug Discovery & Development